EUCTR2018-001082-17-HU
Active, not recruiting
Phase 1
A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched population with surgical site infections - DRESS - DELAFLOXACIN INTRAVENOUS AND ORAL MONOTHERAPY
MENARINI RICERCHE S.p.A.0 sites600 target enrollmentJune 6, 2019
ConditionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
DrugsBAXDELA
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Acute Bacterial Skin and Skin Structure Infection
- Sponsor
- MENARINI RICERCHE S.p.A.
- Enrollment
- 600
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female patients aged more than 18 years.
- •2\. Patients with a history of cardiothoracic / related leg or abdominal surgery, occurred within 30 days and no implant is left in place, and a diagnosis of SSI according to the CDC definition1, namely:
- •\- Superficial Incisional Surgical Site Infection, involving only skin and subcutaneous tissue of the incision, and at least one of the following local findings:
- •· purulent drainage from the superficial incision;
- •· organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision;
- •· superficial incision is deliberately explored by surgeon AND the patient has at least one of the following signs or symptoms of infection:
- •\* pain or tenderness,
- •\* localized swelling,
- •\* redness or heat;
- •· diagnosis of superficial incisional SSI made by the Investigator.
Exclusion Criteria
- •1\. Previous IV antimicrobial therapy exceeding 24 hour duration administered during 72 hours prior to the first dose of study treatment.
- •2\. Any infection expected to require systemic antimicrobial agents other than study treatment(s)
- •5\. Medical history of myasthenia gravis.
- •6\. Medical history of C. difficile diarrhea.
- •8\. Organ\-space infection.
- •13\. Use of systemic corticosteroids for more than 10 days at a dose equivalent to more than 15 mg prednisolone in the previous 2 weeks.
- •14\. Patients with end\-stage renal disease on hemodialysis or peritoneal dialysis or creatinine clearance (CrCl) \< 15 mL/min using the Cockcroft\-Gault formula.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-001082-17-ATMENARINI RICERCHE S.p.A.600
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-001082-17-CZMENARINI RICERCHE S.p.A.600
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-001082-17-ROMENARINI RICERCHE S.p.A.266
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-001082-17-HRMENARINI RICERCHE S.p.A.600
Active, not recruiting
Phase 1
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2018-001082-17-GBMENARINI RICERCHE S.p.A.600